In this edition:
Non-invasive imaging will replace skin biopsy
Biologics should be first line for hidradenitis suppurativa
Nemolizumab for prurigo nodularis
Spesolimab for prevention of generalised pustular psoriasis flares
Predicting and preventing severe drug reactions using genetic analysis
JAK inhibitors and small molecules
Targeted and pipeline therapeutics in vitiligo
Can we cure psoriasis?
JAK inhibitors vs biologics risk of cancer and opportunistic infections
Draft European hidradenitis suppurativa guidelines
Please login below to download this issue (PDF)